Group 2 data available to date support primary safety and feasibility endpoints of single-day bolus dosing of CT-0508
New translational analyses combining group 1 & group 2 continue to support CAR-M mechanism of action, demonstrating a correlation between biomarkers and best overall response
Read more at prnewswire.com